13.70
+0.22(+1.63%)
Currency In USD
| Previous Close | 13.48 |
| Open | 13.5 |
| Day High | 13.7 |
| Day Low | 13.44 |
| 52-Week High | 16.66 |
| 52-Week Low | 6.38 |
| Volume | 704,477 |
| Average Volume | 1.34M |
| Market Cap | 1.32B |
| PE | -685 |
| EPS | -0.02 |
| Moving Average 50 Days | 10.54 |
| Moving Average 200 Days | 9.69 |
| Change | 0.22 |
If you invested $1000 in Avadel Pharmaceuticals plc (AVDL) 10 years ago, it would be worth $651.76 as of August 20, 2025 at a share price of $13.7. Whereas If you bought $1000 worth of Avadel Pharmaceuticals plc (AVDL) shares 5 years ago, it would be worth $1,585.65 as of August 20, 2025 at a share price of $13.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
GlobeNewswire Inc.
Jul 31, 2025 12:00 PM GMT
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
GlobeNewswire Inc.
Jun 30, 2025 11:00 AM GMT
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the Distr
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
GlobeNewswire Inc.
Jun 05, 2025 11:30 AM GMT
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from